Predictive Oncology Inc. (POAI)
Automate Your Wheel Strategy on POAI
With Tiblio's Option Bot, you can configure your own wheel strategy including POAI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol POAI
- Rev/Share 0.1882
- Book/Share -0.0204
- PB -46.6035
- Debt/Equity -13.1573
- CurrentRatio 0.7563
- ROIC -5.5923
- MktCap 8485039.0
- FreeCF/Share -1.1956
- PFCF -0.9923
- PE -0.8045
- Debt/Assets 0.3269
- DivYield 0
- ROE -5.9137
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | POAI | H.C. Wainwright | -- | Buy | -- | $3 | Aug. 19, 2024 |
News
AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company Leverages More Than Twenty Years of Drug Response Data Derived from Massive Biobank of Live Cell Tumor Samples Company Leverages More Than Twenty Years of Drug Response Data Derived from Massive Biobank of Live Cell Tumor Samples
Read More
Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company successfully developed predictive models derived from 21 unique compounds from the Natural Products Discovery Core at the University of Michigan
Read More
Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Deal positions STREAMWAY ® Systems with an established market leader to drive accelerating growth
Read More
Predictive Oncology Closes Registered Direct Offering
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), a leader in AI-driven drug discovery and biologics, today closed its previously announced registered direct offering for the purchase and sale of 363,336 shares of common stock at a purchase price of $1.50 per share priced at-the-market under Nasdaq rules.
Read More
Predictive Oncology Reports Positive Results Utilizing Artificial Intelligence for Drug Repurposing
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company successfully identified several abandoned or discontinued drugs for further testing and development in ovarian and other cancer types
Read More
Certis Oncology Announces Issuance of U.S. Patent for Its Proprietary CertisAI Predictive Oncology Intelligence™ Platform
Published: February 12, 2025 by: Business Wire
Sentiment: Neutral
SAN DIEGO--(BUSINESS WIRE)-- #CertisAI--Certis Oncology Solutions, a precision oncology and translational science company, announced today that the United States Patent and Trademark Office (USPTO) has allowed a patent application directed to Certis's predictive artificial intelligence/machine learning (AI/ML) platform, CertisAI™. “The patent marks an important milestone for our company,” said Peter Ellman, President and CEO of Certis. “It substantiates the uniqueness of our proprietary platform and the un.
Read More
About Predictive Oncology Inc. (POAI)
- IPO Date 2010-05-03
- Website https://www.predictive-oncology.com
- Industry Medical - Instruments & Supplies
- CEO Mr. Raymond F. Vennare
- Employees 23